Delgocitinib Cream Update: Leo’s Topical Pan JAK Inhibitor Hits All Primary and Secondary Endpoints in Phase 3 CHE Trials
Delgocitinib cream met the primary and secondary endpoints in the DELTA 1 and DELTA 2 Phase 3 severe chronic hand eczema (CHE) trials. Leo’s delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor, is under investigation and has not been approved by any health authority. The primary objective for the randomized, double-blind, vehicle-controlled, multi-center phase 3 […]